 All patients will have 13 mL of bloodday drawn at baseline, day 3, day 8 and at the end of the treatment period on day 14 or last day of treatment. The samples will be prepared on site and shipped to a central lab for processing. The investigators will use the blood specimens to measure markers of inflammation C-reactive protein, Procalcitonin, and Interleukin-6 and others as determined by the investigators, markers of candida presence b-glucan and other potential future markers and markers of immune dysfunction to be determined by investigators. 